CO5190702A1 - METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS - Google Patents
METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORSInfo
- Publication number
- CO5190702A1 CO5190702A1 CO00053308A CO00053308A CO5190702A1 CO 5190702 A1 CO5190702 A1 CO 5190702A1 CO 00053308 A CO00053308 A CO 00053308A CO 00053308 A CO00053308 A CO 00053308A CO 5190702 A1 CO5190702 A1 CO 5190702A1
- Authority
- CO
- Colombia
- Prior art keywords
- amino
- alkyl
- independently selected
- halo
- hydroxyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
Un método para tratar el dolor crónico, dicho método caracterizado porque comprende administrar a un sujeto que necesita tal tratamiento, una composición que comprende un inhibidor de MEK seleccionado del compuesto de la fórmula<EMI FILE="00053308_1" ID="1" IMF=JPEG >W es una de las siguientes fórmulas (i) - (xiii):<EMI FILE="00053308_2" ID="2" IMF=JPEG >X1 es O, S, o NRF;X2 es OH, SH o NHRE,cada uno de RE y RF es H o alquilo de C1-4; cada uno de R1 y R2 se selecciona independientemente de H, F, NO2, Br y Cl; R1 también puede ser SO2NRGRH o R1 y R2 junto con el anillo de benceno al cual están unidos constituyen indol, isoindol, benzofurano, benzotiofeno, indazol, bencimidazol, o benzotioazol;R3 es H y F;cada uno de RG, RH y R4 se selecciona independientemente de H, Cl y CH3; R5 es H o alquilo de C1-4;donde cada radical de hidrocarburo de arriba es optativamente sustituido con entre 1 y 3 sustituyentes independientemente seleccionados de halo, hidroxilo, amino, (amino)sulfonilo y NO2; y donde cada radical heterocíclico de arriba es optativamente sustituido con entre 1 y 3 sustituyentes seleccionados independientemente de halo, alquilo de C1-4, cicloalquilo de C3-6, alquenilo de C3-4, alquinilo de C3-4, fenilo, hidroxilo amino, (amino) sulfonilo, y NO2, en donde cada sustituyente alquilo, cicloalquilo, alquenilo, alquinilo o fenilo es a su vez optativamente sustituido con entre 1 y 2 sustituyentes seleccionados independientemente de halo, alquilo de C1-2, hidroxilo, amino y NO2; o una sal farmacéuticamente aceptable o un éster de C1-8 de él.A method for treating chronic pain, said method characterized in that it comprises administering to a subject in need of such treatment, a composition comprising an MEK inhibitor selected from the compound of the formula <EMI FILE = "00053308_1" ID = "1" MFI = JPEG> W is one of the following formulas (i) - (xiii): <EMI FILE = "00053308_2" ID = "2" IMF = JPEG> X1 is O, S, or NRF; X2 is OH, SH or NHRE, each of RE and RF is H or C1-4 alkyl; each of R1 and R2 is independently selected from H, F, NO2, Br and Cl; R1 may also be SO2NRGRH or R1 and R2 together with the benzene ring to which they are attached constitute indole, isoindol, benzofuran, benzothiophene, indazole, benzimidazole, or benzothioazole; R3 is H and F; each of RG, RH and R4 is independently selects H, Cl and CH3; R5 is H or C1-4alkyl, wherein each hydrocarbon radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, hydroxyl, amino, (amino) sulfonyl and NO2; and wherein each heterocyclic radical above is optionally substituted with between 1 and 3 substituents independently selected from halo, C1-4 alkyl, C3-6 cycloalkyl, C3-4 alkenyl, C3-4 alkynyl, phenyl, amino hydroxyl, (amino) sulfonyl, and NO2, wherein each alkyl, cycloalkyl, alkenyl, alkynyl or phenyl substituent is in turn optionally substituted with between 1 and 2 substituents independently selected from halo, C1-2 alkyl, hydroxyl, amino and NO2; or a pharmaceutically acceptable salt or a C1-8 ester thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14440399P | 1999-07-16 | 1999-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5190702A1 true CO5190702A1 (en) | 2002-08-29 |
Family
ID=22508429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00053308A CO5190702A1 (en) | 1999-07-16 | 2000-07-14 | METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1202732A2 (en) |
JP (1) | JP2003504399A (en) |
KR (1) | KR20020015379A (en) |
CN (1) | CN1358095A (en) |
AU (1) | AU5785900A (en) |
CA (1) | CA2377100A1 (en) |
CO (1) | CO5190702A1 (en) |
HK (1) | HK1047039A1 (en) |
HU (1) | HUP0202381A3 (en) |
IL (1) | IL147617A0 (en) |
PE (1) | PE20010547A1 (en) |
PL (1) | PL352705A1 (en) |
TR (1) | TR200200204T2 (en) |
UY (1) | UY26248A1 (en) |
WO (1) | WO2001005391A2 (en) |
ZA (1) | ZA200109903B (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG148857A1 (en) | 2002-03-13 | 2009-01-29 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US20050004186A1 (en) * | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
EP1682495A1 (en) | 2003-10-21 | 2006-07-26 | Warner-Lambert Company LLC | Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
AU2004293019B2 (en) | 2003-11-19 | 2010-10-28 | Array Biopharma Inc. | Bicyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
KR101223914B1 (en) | 2003-11-21 | 2013-01-18 | 어레이 바이오파마 인크. | Akt protein kinase inhibitors |
US7956191B2 (en) | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
TWI441637B (en) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Heterocyclic inhibitors of mek and methods of use thereof |
EA019983B1 (en) | 2005-10-07 | 2014-07-30 | Экселиксис, Инк. | Mek inhibitors and methods of using same |
WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
MY147628A (en) | 2006-07-06 | 2012-12-31 | Array Biopharma Inc | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
DE602007011628D1 (en) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
AU2007326395B2 (en) * | 2006-12-01 | 2012-10-11 | Msd K.K. | Novel phenyl-isoxazol-3-ol derivative |
CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
AU2008206045A1 (en) * | 2007-01-19 | 2008-07-24 | Ardea Biosciences, Inc. | Inhibitors of MEK |
CA2692506C (en) | 2007-07-05 | 2015-11-24 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
CN103396409B (en) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
EP2240455B1 (en) | 2008-01-09 | 2012-12-26 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
CA2711699A1 (en) | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
ES2399384T3 (en) | 2008-11-10 | 2013-04-01 | Bayer Schering Pharma Ag | Sulfonamido substituted phenoxybenzamides |
CA2777430A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
US8962606B2 (en) | 2009-10-21 | 2015-02-24 | Bayer Intellectual Property Gmbh | Substituted benzosulphonamides |
EP2491014A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
SG194048A1 (en) | 2011-04-01 | 2013-11-29 | Genentech Inc | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
CN103841976A (en) | 2011-04-01 | 2014-06-04 | 基因泰克公司 | Combinations of AKT AND MEK inhibitor compounds, and methods of use |
SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | Novel process for making compounds for use in the treatment of cancer |
US11186554B2 (en) | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
US11192865B2 (en) | 2017-08-21 | 2021-12-07 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
US11661403B2 (en) | 2018-05-16 | 2023-05-30 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
ES2274572T3 (en) * | 1997-07-01 | 2007-05-16 | Warner-Lambert Company Llc | ACID DERIVATIVES 2- (4-BROMO- OR 4-IODO-PHENYLAMINE) BENZOIC AND ITS USE AS A MEK INHIBITOR. |
JP2002532415A (en) * | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Treatment of arthritis with MEK inhibitors |
CZ20012528A3 (en) * | 1999-01-13 | 2002-06-12 | Warner-Lambert Company | 1-Heterocyclically substituted diaryl amines, pharmaceutical compositions based thereon and treatment methods |
-
2000
- 2000-07-05 KR KR1020027000665A patent/KR20020015379A/en not_active Application Discontinuation
- 2000-07-05 JP JP2001510448A patent/JP2003504399A/en active Pending
- 2000-07-05 CA CA002377100A patent/CA2377100A1/en not_active Abandoned
- 2000-07-05 WO PCT/US2000/018346 patent/WO2001005391A2/en not_active Application Discontinuation
- 2000-07-05 PL PL00352705A patent/PL352705A1/en unknown
- 2000-07-05 TR TR2002/00204T patent/TR200200204T2/en unknown
- 2000-07-05 CN CN00809525A patent/CN1358095A/en active Pending
- 2000-07-05 EP EP00943382A patent/EP1202732A2/en not_active Withdrawn
- 2000-07-05 AU AU57859/00A patent/AU5785900A/en not_active Abandoned
- 2000-07-05 IL IL14761700A patent/IL147617A0/en unknown
- 2000-07-05 HU HU0202381A patent/HUP0202381A3/en unknown
- 2000-07-14 PE PE2000000703A patent/PE20010547A1/en not_active Application Discontinuation
- 2000-07-14 CO CO00053308A patent/CO5190702A1/en not_active Application Discontinuation
- 2000-07-14 UY UY26248A patent/UY26248A1/en not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109903A patent/ZA200109903B/en unknown
-
2002
- 2002-11-29 HK HK02108607.6A patent/HK1047039A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001005391A3 (en) | 2001-07-19 |
HUP0202381A2 (en) | 2002-11-28 |
AU5785900A (en) | 2001-02-05 |
CN1358095A (en) | 2002-07-10 |
PL352705A1 (en) | 2003-09-08 |
TR200200204T2 (en) | 2002-11-21 |
CA2377100A1 (en) | 2001-01-25 |
WO2001005391A2 (en) | 2001-01-25 |
ZA200109903B (en) | 2003-05-28 |
KR20020015379A (en) | 2002-02-27 |
IL147617A0 (en) | 2002-08-14 |
PE20010547A1 (en) | 2001-06-04 |
HUP0202381A3 (en) | 2004-12-28 |
EP1202732A2 (en) | 2002-05-08 |
JP2003504399A (en) | 2003-02-04 |
HK1047039A1 (en) | 2003-02-07 |
UY26248A1 (en) | 2000-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5190702A1 (en) | METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS | |
PE20230238A1 (en) | KRAS G12C INHIBITORS | |
ATE360630T1 (en) | AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR | |
DOP2004001052A (en) | 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO | |
EA200000871A1 (en) | PHOSPHOLIPASE ENZYME INHIBITORS | |
RU2203274C2 (en) | Spirocyclic inhibitors of metalloproteases | |
ATE416161T1 (en) | INDOLES SUITABLE FOR THE TREATMENT OF INFLAMMATION | |
DE60114994D1 (en) | PLATELET ADP RECEPTOR INHIBITORS | |
CO5160273A1 (en) | PROCEDURES AND INTERMEDIATES TO PREPARE ANTI-TARGET COMPOUNDS DERIVED FROM QUINAZOLINA | |
AR012264A1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION AND METHOD TO OBTAIN THE COMPOSITION TO PREVENT OR AVOID A DISEASE ASSOCIATED WITH UNDESIATED METALOPROTEASICAL ACTIVITY | |
EA200400073A1 (en) | Pyrrolipyrimins as inhibitors of protein kinases | |
GEP20053720B (en) | Triamide-Substituted Indoles, Benzofuranes and Benzothiophenes as Inhibitors of Microsomal Triglyceride Transfer Protein (MTP) and/or Apolipoprotein B (Apo B) Secretion | |
DK1697371T3 (en) | Azabicyclic heterocyclic compounds as cannabinoid receptor modulators | |
RU2010125121A (en) | Biaryl-substituted derivatives of azabicyclic alkanes | |
RU2002115284A (en) | COMPOUNDS OF 5-ARIL-1H-1,2,4-TRIAZOLE AS CYCLOOXYGENASE-2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
RU97117350A (en) | INTIMA HYPERTROPHY INHIBITOR, OXINDOL DERIVATIVE APPLICATION FOR THE INIMA HYPERTROPHY INHIBITOR INHIBITOR, A COMPOSITION FOR INHIBITING INTIMA HYPERTROPHY, PREVENTION AND TREATMENT HYPERT | |
ES2155093T3 (en) | NEW INHIBITORS OF URIDINA FOSFORILASA (URDPASA) AND DIHIDROURACIL DESHIDROGENASA (DHUDASA). | |
NO20025510D0 (en) | Tienodibenzoazulen compounds as tumor necrosis factor inhibitors | |
CO5420196A1 (en) | INHIBITING COMPOUNDS OF METALOPROTEASE BIDENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR USE | |
CO5090829A1 (en) | ORGANIC COMPOUNDS OF FORMULA I, USED AS INHIBITED RES OF THE PROTEIN OF TRANSFER OF MICROSOUS TRIGLICERIDE AND OF THE APOLIPOPROTEIN B SECRETION. | |
CO5160295A1 (en) | NEW PHARMACEUTICAL COMBINATIONS FOR INHIBITORS OF THE US A SSRI | |
ATE430132T1 (en) | INDOLES SUITABLE FOR THE TREATMENT OF INFLAMMATION | |
RU2011100106A (en) | SUBSTITUTED BENZIMIDAZOLE FOR TREATMENT OF NEUROFIBROMATOSIS | |
RU2003128068A (en) | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR APPLICATION IN PHARMACY | |
ATE133169T1 (en) | INDOLE DERIVATIVES AS ''5-HT1-LIKE'' AGONISTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |